Top Tweets for #KeyMed
🇨🇳 #KeyMed registered a Ph3 trial for its CD3/BCMA bispecific antibody CM336. It is the first Ph3 trial for CM336. https://t.co/LD02UKwr7H
It is a randomized, open-label, multicenter clinical trial (n=280) aimed at evaluating the efficacy and safety of CM336 monotherapy compared to investigator-chosen standard treatment regimens in patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least two prior lines of therapy.
The primary endpoint of the study is progression-free survival (PFS).
Previously, CM336 has completed a Phase I/II study in R/R MM. In the dose-escalation cohort, 23 patients were evaluable for efficacy.
The results showed that, with a median follow-up of 12.1 months, the objective response rates (ORR) in the ≤5mg group, 20-40mg group, and 80-160mg group were 17%, 71%, and 80%, respectively. The proportions of patients achieving stringent complete response or complete response were 17%, 71%, and 60%, respectively.
Keymed granted #NewCo PML (Platina Medicines) the rights of CM336 to outside of Greater China in Nov. 2024. https://t.co/vSz1mDBRJ0
1/🇨🇳 #Keymed Biosciences announced that its BCMA/CD3 bispecific antibody CM336 will enter the global market via NewCo strategy, granting PML (Platina Medicines) the rights of CM336 to outside of Greater China. https://t.co/hH3Hbkm0G3
🇨🇳 #Keymed Biosciences announced that recently published a research report titled "BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy" in NEJM https://t.co/CDLXdZAPuf , which has reported for the first time globally the research data on a BCMA x CD3 bispecific antibody treatment for patients with refractory autoimmune hemolytic anemia (AIHA). https://t.co/FpJobbQR8P
Both patients showed rapid improvement with partial remission by day 13 (Patient 1) and day 19 (Patient 2); hemoglobin levels normalized by day 17 and day 21, respectively.
🇨🇳 #Keymed Bioscience has registered a Ph1/2 study of its CDH17 ADC CM518D1 for the treatment of advanced solid tumors in #China. This is the first clinical trial for the drug.
This is a multicenter, open-label, Ph1/2 clinical study. The primary endpoints of the study are safety and tolerability (adverse events, laboratory tests, dose-limiting toxicities, etc.) and efficacy (objective response rate [ORR] assessed by RECIST v1.1).
![chuminhua432's tweet photo. 🇨🇳 #Keymed Bioscience has registered a Ph1/2 study of its CDH17 ADC CM518D1 for the treatment of advanced solid tumors in #China. This is the first clinical trial for the drug.
This is a multicenter, open-label, Ph1/2 clinical study. The primary endpoints of the study are safety and tolerability (adverse events, laboratory tests, dose-limiting toxicities, etc.) and efficacy (objective response rate [ORR] assessed by RECIST v1.1).](https://pbs.twimg.com/media/Gsv20KhaUAA0j2f.jpg)
![chuminhua432's tweet photo. 🇨🇳 #Keymed Bioscience has registered a Ph1/2 study of its CDH17 ADC CM518D1 for the treatment of advanced solid tumors in #China. This is the first clinical trial for the drug.
This is a multicenter, open-label, Ph1/2 clinical study. The primary endpoints of the study are safety and tolerability (adverse events, laboratory tests, dose-limiting toxicities, etc.) and efficacy (objective response rate [ORR] assessed by RECIST v1.1).](https://pbs.twimg.com/media/Gsv2s2OaUAAwluw.jpg)
On April 15, Chengdu held the Citywide Conference on #OpeningUp and #Development, aiming to accelerate the city’s transformation into a more competitive and influential hub for international engagement.
Jia Xi, Senior VP of #KeyMed Biosciences (Chengdu), said:
“We’re able to attract more partners to #Chengdu, grow together with the city, and love Chengdu even more!”
1）🇨🇳 #Keymed Biosciences announce that it and #Timberlyne Therapeuticshave entered into an exclusive out-#license agreement. The License Agreement grants Timberlyne the exclusive right of CM313 globally excluding Greater China. https://t.co/TaqbnmFJ8N
1/🇨🇳 #Keymed Biosciences announced that its BCMA/CD3 bispecific antibody CM336 will enter the global market via NewCo strategy, granting PML (Platina Medicines) the rights of CM336 to outside of Greater China. https://t.co/hH3Hbkm0G3
Remonter ses manches et créer sa propre MSP spécialisée dans le sport. Utiliser cette expérience pour accompagner des confrères avec #Keymed... Amina Fouzai passe La Consult' !
Thank you @OlympusUK #KeyMed for allowing @CR_UK to raise funds in your canteen today. #sarcoma #ForKate #lookinglikechristmas
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers